Poland· PL-100511714
Penbraya
A meningococcal vaccines product containing szczepionka skoniugowana przeciw meningokokom grup a, c, w i y oraz grupy b (rekombinowana, adsorbowana), registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Szczepionka skoniugowana przeciw meningokokom grup a, c, w i y oraz grupy b (rekombinowana, adsorbowana) is registered in 5 of 19 countries.
Countries holding a registration under ATC J07AH (meningococcal vaccines), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Szczepionka skoniugowana przeciw meningokokom grup a, c, w i y oraz grupy b (rekombinowana, adsorbowana) · ATC J07AH
5 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Szczepionka skoniugowana przeciw meningokokom grup A, C, W i Y oraz grupy B (rekombinowana, adsorbowana)
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Poland (PL)
- ATC code
- J07AH
- ATC class
- Meningococcal vaccines
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AH
Meningococcal vaccines, as other registers publish it.
- BelgiumMenjugate Kit 10 µgGSK Vaccines
- CanadaMENJUGATE LIQUIDGLAXOSMITHKLINE INC
- IrelandNeisVac-C 0.5 ml Suspension for injection in pre-filled syringe. Meningococcal Group C Polysaccharide Conjugate Vaccine AdsorbedPfizer Healthcare Ireland Unlimited Company
- FinlandPenbrayaPfizer Europe MA EEIG
- CanadaTRUMENBAPFIZER CANADA ULC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/39090db4-fd89-49ba-9e9a-ce877f7d62a5 GET /v1/drugs/39090db4-fd89-49ba-9e9a-ce877f7d62a5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i zawiesina do sporządzania zawiesiny do wstrzykiwań",
"source": "urpl",
"strength": "1 dawka (0,5 ml)",
"packaging": "Rp ¦ EU/1/24/1871/001 ¦ 159913\n1 amp.-strzyk. 0,5 ml z zawiesiną + adapter fiolki ¦ 1 fiol. 1 dawka proszku ¦ 1 igła \nRp ¦ EU/1/24/1871/005 ¦ 159931\n5 fiol. ¦ 5 amp.-strzyk. 0,5 ml + 5 adapterów\nRp ¦ EU/1/24/1871/006 ¦ 159932\n10 amp.-strzyk. 0,5 ml + 10 adapterów ¦ 10 fiol. \nRp ¦ EU/1/24/1871/002 ¦ 159933\n5 igieł + 5 adapterów fiolki ¦ 5 amp.-strzyk. 0,5 ml z zawiesiną ¦ 5 fiol. \nRp ¦ EU/1/24/1871/004 ¦ 159934\n1 amp.-strzyk. 0,5 ml ¦ 1 fiol. + 1 adapter\nRp ¦ EU/1/24/1871/003 ¦ 159935\n10 fiol. + 10 adapterów fiolki ¦ 10 amp.-strzyk. 0,5 ml ¦ 10 igieł",
"substance": "polisacharyd Neisseria meningitidis grupy A 5 mcg + polisacharyd Neisseria meningitidis grupy C 5 mcg + polisacharyd Neisseria meningitidis grupy W 5 mcg + polisacharyd Neisseria meningitidis grupy Y 5 mcg",
"common_name": "Szczepionka skoniugowana przeciw meningokokom grup A, C, W i Y oraz grupy B (rekombinowana, adsorbowana)",
"pl_product_id": "100511714",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": "2025-01-20"
}See everything about szczepionka skoniugowana przeciw meningokokom grup a, c, w i y oraz grupy b (rekombinowana, adsorbowana).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.